As it is important to find therapeutic solutions in the early stages of the pathogenesis of these complex diseases before advanced symptoms appear, we exposed WT and Tff3-deficient mice to 9 weeks of HFD treatment and observed the effects on various features of metabolic disorders, including insulin and glucose metabolism, the accumulation of lipids in the liver, and underlying molecular alterations. The gene discussed is INS; the disease is Other metabolic disease.